

- Esophagitis (*Cont.*):
 diagnosis of, 1894
 endoscopic findings in, 1896f
 eosinophilic. *See* Eosinophilic esophagitis
 in GERD. *See* Gastroesophageal reflux disease (GERD)
 in HIV infection, 1256, 1256f, 1909–1910, 1909f
 infectious, 1909
 Candida. *See* *Candida* spp. infections, esophageal
 CMV, 1896f, 1910
 HSV, 1179, 1182t, 1896f, 1910
 peptic, 1907f
 pill-induced, 257, 1910
 radiation, 1910
 treatment of, 263
- Esophagogastroduodenoscopy, 1881, 1881f, 1882f, 1901
- Esophagogastrosomy, 257
- Esophagoscopy, 533
- Esophagus
 anatomy of, 255, 1900
 Barrett's. *See* Barrett's esophagus/metaplasia
 "corkscrew," 1905, 1907f
 foreign bodies in, 1891–1892, 1893f, 1911
 functions of, 1900
 gastric juice effects on, 1906–1907
 jackhammer, 1907f
 scleroderma, 1911
 systemic disease effects on, 1911
- ESR. *See* Erythrocyte sedimentation rate (ESR)
- ESRD (end-stage renal disease). *See* Chronic kidney disease (CKD), stage 5
- Essential fructosuria, 433e-3t, 433e-5
- Essential mixed cryoglobulinemia, 2189.
See also Cryoglobulinemia
- Essential thrombocytosis (ET), 672, 676
- Essential tremor, 2612t, 2619–2620
- Estazolam, 473e-10t
- Esthesioneuroblastoma, 119e-4
- Estimated average requirement, 95e-1
- Estramustine, 103e-12t, 103e-15
- Estrogen(s)
 actions of, 2377f
 bone remodeling and, 2491–2492, 2492f, 2498
 breast cancer and, 524
 carcinogenicity of, 477t
 cardioprotective action of, 6e-2–3
 deficiency of, 6e-4
 excess of, 2366
 neuroprotective action of, 6e-2
 in perimenopause, 2381, 2381f
 production of, 2359f, 2377, 2377f
 reference values for, 2759
- Estrogen receptors
 action of, 2378, 2498
 in breast cancer, 102e-7, 526, 528
 in carcinoma of unknown primary, 120e-2t
- Estrogen therapy. *See also* Postmenopausal hormone therapy
 for adult hypopituitarism, 2259t
 adverse effects of, 2498, 2498f
 cholestasis, 2023, 2025t
 cutaneous, 353
 edema, 253t
 erectile dysfunction, 327
 hypertension, 1617t
 lipoprotein disorders, 2443–2444
 for amenorrhea, 337
 colorectal cancer and, 478, 539
 for contraception. *See* Contraception
 coronary heart disease and, 291e-7–8
 endometrial cancer and, 596
 for female sexual dysfunction, 331
 for hirsutism, 334
 for hypogonadism, 2261
 for migraine prevention, 2593t
 for osteoporosis, 2497–2498
 for Turner's syndrome, 2352
 vaginal, 2383, 2386
- Eszopiclone, 191, 215
- ET. *See* Essential thrombocytosis (ET)
- Etanercept
 action of, 372e-30
 adverse effects of, 348t, 422, 834, 2146t, 2173
 for ankylosing spondylitis, 2172–2173
 monitoring during treatment with, 2146t
 for psoriasis/psoriatic arthritis, 348t, 2177
 for rheumatoid arthritis, 2145, 2146t
 for sarcoidosis, 2211–2212
- ETEC. *See* Enterotoxigenic *E. coli* (ETEC)
- E-test, 150e-9
- Ethacrynic acid, 322, 1624t
- Ethambutol
 action of, 205e-4
 adverse effects of, 205e-4
 gout, 2218t
 neuropathy, 2687t
 optic neuritis, 205e-4
 optic neuropathy, 203
 thrombocytopenia, 727t
 zinc deficiency, 96e-9
 dosage of, 205e-4
 for MAC infection prophylaxis, 1251t
 for nontuberculous mycobacterial infections, 205e-4, 205e-8, 1131–1132, 1696
 pharmacology of, 205e-4
 resistance to, 205e-4, 1118
 for TB, 205e-2t, 205e-4, 1115–1117, 1115t, 1116t
 for tuberculous meningitis, 898
- Ethanol
 beverage. *See* Alcohol
 for ethylene glycol poisoning, 64e-9, 319
 injection, for hepatocellular carcinoma, 549
- Ethchlorvynol, 203, 473e-11t
- Ethical issues, 17e-1
 acting in best interests of patient, 17e-2
 avoiding deception, 17e-1
 clinical practice guidelines and, 17e-3
 confidentiality, 17e-1
 conflicts between patient's choices and their best interests, 17e-2
 conflicts of interest, 17e-3–4
 futile care, 67
 in genetic testing, 445
 in global health field experiences, 17e-3
 informed consent, 17e-1
 justice, 17e-2
 new technologies and, 7
 patient autonomy, 17e-1
 patient who lacks decision-making capacity, 17e-1–2
 personal values and, 17e-2–3
 professional oaths and codes and, 17e-2
 in social media use, 17e-3
 in stem cell therapy, 90e-4
 in team-based care, 17e-3
 virtue ethics, 17e-2
 work hour limitations and, 17e-3
- Ethinyl estradiol, 334, 2382, 2391. *See also* Estrogen therapy
- Ethionamide, 205e-6, 1116t
- Ethnic groups. *See also* Racial/ethnic disparities in health care
 drug responses in, genetic basis, 40
 waist circumference values in, 2394t
- Ethosuximide, 473e-10t, 2553t, 2556, 2765t
- Ethylendiaminetetraacetic acid (EDTA), 2237
- Ethylene glycol poisoning
 acidosis in, 64e-9, 319
 acute kidney injury in, 1804
 clinical features of, 473e-11t
 diagnosis of, 64e-9, 1805
 laboratory evaluation of, 2765t
 mechanism of, 473e-11t
 optic neuropathy in, 203
 treatment of, 64e-9, 319, 473e-11t
- Ethylene oxide, 2688t
- Ethynodiol diacetate, 334
- Etidronate
 for hypercalcemia, 610, 2481
 for osteoporosis management/prevention, 2499
 for Paget's disease of bone, 426e-3, 426e-3t
- Etomidate
 for Cushing's syndrome, 2273, 2318
 in mechanical ventilation, 1741
 overdose/poisoning with, 473e-10t
- Etoposide
 action of, 103e-13
 adverse effects of, 103e-10t, 103e-13, 590
 acute leukemia, 103e-13
 gonadal dysfunction, 103e-25
 nausea and vomiting, 103e-25
 neurologic, 1793, 2686t
 for breast cancer, 531
 drug interactions of, 1793
 for Ewing's sarcoma, 119e-4
 for gestational trophoblastic disease, 124e-5, 597
 for lung cancer, 522
 for ovarian germ cell tumors, 594
 for soft tissue sarcoma, 119e-2
 for testicular cancer, 590, 591
- Etravirine
 adverse effects of, 1274t, 1278
 for HIV, 1278
 for HIV infection, 1274t
 molecular structure of, 1276f
 resistance to, 1279f
- Etretinate, 2199
- Eukaryotes, in human microbiome, 86e-4
- Eumycetoma, 1355, 1356
- Eunuchoid proportions, 2360
- European bat lyssaviruses, 1304
- European fire ants, 2749
- EUS. *See* Endoscopic ultrasound (EUS)
- Eustachian tube dysfunction, 217
- Euthanasia, 67–68, 67t
- Euthyroid hyperthyroxinemia, 2286, 2286t
- EV1 overexpression, 680, 680t
- Evacuation disorders, 272
- Evaporative cooling, 479e-3
- Everglades virus, 1306t
- Everolimus
 action and targets of, 102e-5t, 103e-16f, 103e-18t, 103e-19, 1829t
 adverse effects of, 102e-5t, 103e-18t, 103e-19, 103e-26, 574, 1829t, 2071
 for breast cancer, 102e-5t, 103e-19, 530
 in drug-eluting stents, 296e-2
 for immunosuppression, 1829, 1829t, 2071
 for insulinoma, 569
 for NETs, 562, 574–575
 for reducing skin cancer risk in transplant recipients, 388
 for renal cell carcinoma, 102e-5t, 579
 therapeutic monitoring of, 2765t
- Evidence-based medicine, 3, 18, 24–26
- Evidence-Based Medicine Reviews, 25t
- Evoked potentials, 442e-3–4, 2665, 2665t
- Ewingii ehrlichiosis, 1155t, 1160
- Ewing's sarcoma, 119e-4
 diagnosis of, 119e-4
 genetic considerations in, 101e-3t, 119e-4
 incidence of, 119e-4
 oral manifestations of, 236
 treatment of, 119e-4
 tumor markers in, 473t
- Exanthems. *See* Rash
- Exanthem subitum (roseola), 25e-2f, 127, 128t, 1194
- Exchangers (antiporters), 332e-6
- Exchange transfusion, 636, 1386t, 1387
- Excitable gap reentry, 273e-3, 273e-4, 273e-4f
- Excitation-contraction coupling, genetic defects of, 1555t
- Excitotoxicity, 444e-8–9
- Executive functions, 183
- Exemestane, 103e-15, 478
- Exenatide, 2414, 2414t
- Exercise
 anaphylaxis due to, 2118
 for atherosclerosis prevention, 291e-8t, 291e-9
 for AV conduction block, 1473
 for back pain, 119, 120
 for cancer prevention, 476
 cardiac response to, 265e-8, 265e-9f